Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-4262 antagomir
- Development stage
- Preclinical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
miR-4262 antagomir is a chemically modified, single-stranded antisense oligonucleotide designed to bind to and inhibit the activity of microRNA-4262 (miR-4262). In oncological research, particularly concerning gastric cancer, miR-4262 has been identified as a tumor suppressor that negatively regulates the proto-oncogene CD163. By sequestering miR-4262, the antagomir prevents the microRNA from binding to its target mRNA, thereby increasing the expression of CD163. This inhibition leads to increased cell proliferation and invasion and decreased apoptosis in gastric carcinoma cells, making it a critical tool for studying the miR-4262/CD163 signaling axis in cancer progression.
- Other names
- antagomir-4262antagomir4262antagomir 4262microRNA-4262 antagomirmicroRNA4262 antagomirmicroRNA 4262 antagomiranti-miR-4262anti-miR4262anti-miR 4262
02
Targets
PTEN (Phosphatase and tensin homolog deleted on chromosome ten)
Beyond the preview
Go deeper on miR-4262 antagomir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-4262 antagomir.